Related Experiment Videos
Clinical review of risperidone
1Department of Psychiatry, University of Montreal, Quebec.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|September 1, 1993
Summary
Risperidone is a potent antipsychotic effective for schizophrenia, showing rapid action and a favorable side-effect profile. Long-term use maintains therapeutic benefits without significant neurological issues common with older neuroleptics.
Area of Science:
- Psychiatry and Pharmacology
- Neuroscience
Background:
- Schizophrenia treatment often involves managing positive and negative symptoms.
- Standard neuroleptics can cause significant neurological side-effects, including extrapyramidal symptoms (EPS).
Purpose of the Study:
- To evaluate the efficacy and tolerability of risperidone in Phase II clinical trials for schizophrenia.
- To assess the long-term maintenance of therapeutic effects and safety profile of risperidone.
Main Methods:
- Phase II clinical trials were conducted to assess risperidone's antipsychotic properties.
- Data collection included evaluation of positive and negative symptoms, extrapyramidal symptoms, and parkinsonism.
Main Results:
- Risperidone demonstrated potent antipsychotic effects, improving both positive and negative symptoms of schizophrenia.
- The drug exhibited a low potential for inducing extrapyramidal symptoms and possibly an antidyskinetic effect.
- One-year data indicated sustained therapeutic action in chronic schizophrenia patients without significant neurological side-effects.
Conclusions:
- Risperidone offers a favorable side-effect profile compared to standard neuroleptics.
- Its rapid onset and sustained efficacy make it a promising treatment option for schizophrenia.